Aaron A. is a highly skilled Senior Scientist at Wildtype, specializing in process development focused on upstream operations to enhance salmon cellular yield, with a strong emphasis on next generation animal-component free processes. Prior experience includes significant roles at Sangamo Therapeutics, Inc., where Aaron A. served as CMC Upstream Process Lead for a Fabry clinical drug candidate, leading successful tech transfers and process scaling efforts. Additional expertise encompasses upstream process development for AAV production at the scientist II level, and bioreactor work during a postdoctoral fellowship at AstraZeneca, contributing to advancements in cell culture and metabolic analysis. Aaron A. holds a Ph.D. in Chemical Engineering, along with graduate and undergraduate degrees in Chemical Engineering and Chemistry from the University of Colorado Boulder and the University of Maryland, respectively.